Drug Discovery

Gilead, Merck to study combination therapy for breast cancer

Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC).

Immunai raises funding to expand drug actuary platform

Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform.

Takeda to buy GammaDelta to accelerate allogeneic cell therapies development

Takeda Pharmaceutical has exercised its option to acquire GammaDelta Therapeutics to accelerate development of allogeneic γδT cell therapies to address solid tumours.

Teva, Modag to develop drug candidates for neurodegenerative disease

Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter's drug candidates, anle138b and sery433, for neurodegenerative disease.

Vertex, Mammoth partner to develop in vivo gene-editing therapies

Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases.

EMA’s CHMP begins rolling review of molnupiravir to treat Covid-19 in adults

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine, to treat adult patients with Covid-19.

Atreca, Gates MRI partner to develop antibody for malaria prevention

Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to prevent malaria.

Amgen completes acquisition of biotechnology firm Teneobio

Amgen has completed its previously announced acquisition of a clinical-stage biotechnology firm, Teneobio in a deal worth up to $2.5bn.

Silence Therapeutics, Hansoh partner to develop novel siRNA therapeutics

Silence Therapeutics has announced collaboration with Hansoh Pharmaceutical to develop new therapeutics using Silence’s mRNAi GOLD platform.